MILWAUKEE, June 30, 2025 /PRNewswire/ -- The Ademi Firm is investigating Big 5 (Nasdaq: BGFV) for possible breaches of fiduciary duty and other violations of law in its transaction with Worldwide Golf and Capitol Hill Group.Click here to learn how to join our investigation and obtain additional information or contact us at [email protected] or toll-free: 866-264-3995. There is no cost or obligation to you.In the transaction, shareholders of Big 5 will receive $1.45 per share, with total enterprise value of ...

MILWAUKEE, June 24, 2025 /PRNewswire/ -- The Ademi Firm is investigating Guaranty (NYSE: GNTY) for possible breaches of fiduciary duty and other violations of law in its transaction with Glacier Bancorp.Click here to learn how to join our investigation and obtain additional information or contact us at [email protected] or toll-free: 866-264-3995.  There is no cost or obligation to you.In the tender offer transaction, shareholders of Guaranty will receive 1.0000 share of Glacier stock for each Guaranty shar ...

SAN DIEGO, June 09, 2025 (GLOBE NEWSWIRE) --  Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of DoubleVerify Holdings, Inc. (NYSE: DV) common stock between November 10, 2023 and February 27, 2025, all dates inclusive (the “Class Period”), have until July 21, 2025 to seek appointment as lead plaintiff of the DoubleVerify class action lawsuit. Captioned Electrical Workers Pension Fund, Local 103, I.B.E.W. v. DoubleVerify Holdings, Inc., No. 25-cv-04332 (S.D.N.Y.), the DoubleVerify cla ...

SAN DIEGO, June 05, 2025 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that the Organon class action lawsuit – captioned Hauser v. Organon & Co., No. 25-cv-05322 (D.N.J.) – seeks to represent purchasers or acquirers of Organon & Co. (NYSE: OGN) securities and charges Organon and certain of Organon’s top executives with violations of the Securities Exchange Act of 1934. If you suffered substantial losses and wish to serve as lead plaintiff of the Organon class action lawsuit, please provide ...

Core Viewpoint - The DoubleVerify Holdings, Inc. is facing a class action lawsuit alleging violations of the Securities Exchange Act of 1934, with claims of misleading statements and undisclosed risks impacting the company's stock performance during the specified class period [1][3]. Company Allegations - The lawsuit claims that DoubleVerify's customers shifted ad spending from open exchanges to closed platforms, where the company's technological capabilities were limited, affecting its competitive position [3]. - It is alleged that the development of technology for closed platforms was more expensive and time-consuming than disclosed, limiting DoubleVerify's ability to monetize its Activation Services [3]. - Competitors were reportedly better positioned to incorporate AI into their offerings, which negatively impacted DoubleVerify's profits and competitive edge [3]. - The company is accused of systematically overbilling customers for ad impressions served to bots, and its risk disclosures were misleading, presenting adverse facts as mere possibilities [3]. Stock Performance Impact - Following a lower revenue growth expectation announcement on February 28, 2024, DoubleVerify's stock price fell over 21% [4]. - On May 7, 2024, after cutting its full-year 2024 revenue outlook due to reduced customer ad spending, the stock price dropped nearly 39% [5]. - A report on February 27, 2025, detailing lower-than-expected sales and earnings due to reduced customer spending led to a further stock price decline of more than 36% [6]. Legal Process - Investors who purchased DoubleVerify common stock during the class period can seek appointment as lead plaintiff in the class action lawsuit, representing the interests of all class members [7].

Core Viewpoint - The Organon class action lawsuit alleges that the company and its executives made misleading statements regarding capital allocation and dividend payouts, leading to significant financial losses for investors [1][4]. Company Overview - Organon & Co. develops health solutions through prescription therapies and medical devices [3]. Allegations of the Lawsuit - The lawsuit claims that Organon concealed material information about its capital allocation priorities, particularly regarding the future of its quarterly dividend payout [4]. - It is alleged that Organon's reports on dividend payouts being a "number one priority" were misleading, as they were offset by a newly implemented debt reduction strategy, resulting in a more than 70% decrease in the quarterly dividend [4]. - The lawsuit also states that Organon intended to prioritize debt reduction following its acquisition of Dermavant Sciences Ltd [4]. Financial Impact - On May 1, 2025, Organon reported first quarter 2025 financial results, announcing a reduction in its dividend payout from $0.28 to $0.02, which led to a stock price decline of over 27% [5]. Legal Process - The Private Securities Litigation Reform Act of 1995 allows any investor who purchased Organon securities during the class period to seek appointment as lead plaintiff in the lawsuit [6]. - The lead plaintiff represents the interests of all class members and can select a law firm for litigation [6]. Law Firm Background - Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities fraud and shareholder litigation, having recovered over $2.5 billion for investors in 2024 alone [7]. - The firm has been ranked 1 in securing monetary relief for investors in securities class action cases for four out of the last five years [7].

Core Viewpoint - Kuehn Law, PLLC is investigating potential breaches of fiduciary duties by officers and directors of Bakkt Holdings, Inc. related to misrepresentation of the company's financial stability and revenue sources [1][2]. Group 1: Allegations and Misrepresentation - Insiders at Bakkt allegedly caused the company to misrepresent or fail to disclose critical information regarding the stability and diversity of its crypto services revenue [2]. - It was revealed that Bakkt's crypto services revenue was heavily reliant on a single contract with Webull, raising concerns about revenue sustainability [2]. - The company's ability to maintain key client relationships was also questioned, suggesting that previous positive statements about Bakkt's business and prospects were misleading [2]. Group 2: Shareholder Actions - Shareholders who purchased BKKT shares prior to March 25, 2024, are encouraged to contact Kuehn Law to discuss potential legal actions, as there may be limited time to enforce their rights [3]. - Kuehn Law offers to cover all case costs and does not charge its investor clients, emphasizing the importance of shareholder involvement in maintaining market integrity [4].

NEW YORK, May 28, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Integral Ad Science Holding Corp. (NASDAQ: IAS) breached their fiduciary duties to shareholders. According to a federal securities lawsuit, Insiders at Integral Ad Science caused the company to misrepresent or fail to disclose that (i) that IAS was experiencing a new material trend of increased competitive pricing pressures and that, as a result, IAS had b ...

SAN DIEGO, May 20, 2025 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of West Pharmaceutical Services, Inc. (NYSE: WST) common stock between February 16, 2023 and February 12, 2025, inclusive (the “Class Period”), have until Monday, July 7, 2025 to seek appointment as lead plaintiff of the West Pharmaceutical class action lawsuit. Captioned New England Teamsters Pension Fund v. West Pharmaceutical Services, Inc., No. 25-cv-02285 (E.D. Pa.), the West Pharmaceutic ...

NEW YORK, May 15, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Doximity, Inc. (NYSE: DOCS) breached their fiduciary duties to shareholders. According to a federal securities lawsuit, Insiders at Doximity caused the company to misrepresent or fail to disclose material information concerning the Company’s business and operations. Specifically, the Complaint alleges Defendants repeatedly touted the Company’s business pro ...